{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:38:18Z","timestamp":1791999498345,"version":"4.4.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Cognitive dysfunction affects 40\u201360% of individuals with multiple sclerosis (MS). The neuropsychological profile commonly consists of a subcortical pattern of deficits, although a proportion of patients have a severe progressive cortical dementia. However, patients with MS can be affected by other neurodegenerative diseases, such as Alzheimer\u2019s disease (AD). Little is known about the co-existence of these two conditions but distinguishing dementia due to MS alone from a coexisting neurodegenerative disease is challenging. Amyloid PET imaging has allowed improved AD diagnosis, especially in patients with atypical presentations or multiple possible causes of cognitive impairment. Amyloid PET demonstrates increased cortical signal in AD, whereas reductions in subcortical uptake are associated with demyelination. To the authors knowledge, there are no reports of clinical Amyloid PET use in MS patients with dementia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Here, three MS patients presenting to the Cognitive Neurology Clinic with progressive cognitive impairment are described. Due to lack of diagnostic clarity from standard investigations, they underwent Amyloid PET Imaging with<jats:sup>18<\/jats:sup>F-florbetapir according to established appropriate use criteria and after review by a multidisciplinary team.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Two patients were diagnosed with AD based on positive Amyloid PET imaging and were subsequently started on cholinesterase inhibitor treatment. The other patient had a negative scan, leading to further investigations and identification of another potential cause of worsening cognitive impairment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The experience from this case series suggests that Amyloid PET Imaging may be of diagnostic value in selected patients with MS and dementia. In these individuals, it may provide diagnostic clarity and assist with therapeutic decisions.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s00415-020-09969-z","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T08:02:41Z","timestamp":1592467361000},"page":"3268-3273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Using amyloid PET imaging to diagnose Alzheimer\u2019s disease in patients with multiple sclerosis"],"prefix":"10.1007","volume":"267","author":[{"given":"Magdalena","family":"Kolanko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarni","family":"Win","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neva","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Carswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastassia","family":"Gontsarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Nicholas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1897-0780","authenticated-orcid":false,"given":"Paresh","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,18]]},"reference":[{"issue":"8","key":"9969_CR1","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.neurobiolaging.2010.05.003","volume":"31","author":"LG Apostolova","year":"2010","unstructured":"Apostolova LG, Hwang KS, Andrawis JP, Green AE, Babakchanian S, Morra JH, Cummings JL, Toga AW, Trojanowski JQ, Shaw LM, Jack CR Jr, Petersen RC, Aisen PS, Jagust WJ, Koeppe RA, Mathis CA, Weiner MW, Thompson PM (2010) 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging 31(8):1284\u20131303","journal-title":"Neurobiol Aging"},{"issue":"6","key":"9969_CR2","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nrneurol.2011.61","volume":"7","author":"RH Benedict","year":"2011","unstructured":"Benedict RH, Zivadinov R (2011) Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol 7(6):332\u2013342","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"9969_CR3","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/ana.24620","volume":"79","author":"B Bodini","year":"2016","unstructured":"Bodini B, Veronese M, Garcia-Lorenzo D, Battaglini M, Poirion E, Chardain A, Freeman L, Louapre C, Tchikviladze M, Papeix C, Dolle F, Zalc B, Lubetzki C, Bottlaender M, Turkheimer F, Stankoff B (2016) Dynamic Imaging of Individual Remyelination Profiles in Multiple Sclerosis. Ann Neurol 79(5):726\u2013738","journal-title":"Ann Neurol"},{"issue":"3","key":"9969_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nrn3900","volume":"16","author":"M Calabrese","year":"2015","unstructured":"Calabrese M, Magliozzi R, Ciccarelli O, Geurts JJ, Reynolds R, Martin R (2015) Exploring the origins of grey matter damage in multiple sclerosis. Nat Rev Neurosci 16(3):147\u2013158","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"9969_CR5","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1136\/jnnp-2017-316194","volume":"89","author":"CJ Carswell","year":"2018","unstructured":"Carswell CJ, Win Z, Muckle K, Kennedy A, Waldman A, Dawe G, Barwick TD, Khan S, Malhotra PA, Perry RJ (2018) Clinical utility of amyloid PET imaging with (18)F-florbetapir: a retrospective study of 100 patients. J Neurol Neurosurg Psychiatry 89(3):294\u2013299","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"9969_CR6","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/ana.21240","volume":"63","author":"A Dal Bianco","year":"2008","unstructured":"Dal Bianco A, Bradl M, Frischer J, Kutzelnigg A, Jellinger K, Lassmann H (2008) Multiple sclerosis and Alzheimer's disease. Ann Neurol 63(2):174\u2013183","journal-title":"Ann Neurol"},{"issue":"14","key":"9969_CR7","doi-asserted-by":"publisher","first-page":"e1348","DOI":"10.1212\/WNL.0000000000008198","volume":"93","author":"AJC Eijlers","year":"2019","unstructured":"Eijlers AJC, Dekker I, Steenwijk MD, Meijer KA, Hulst HE, Pouwels PJW, Uitdehaag BMJ, Barkhof F, Vrenken H, Schoonheim MM, Geurts JJG (2019) Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis. Neurology 93(14):e1348\u2013e1359","journal-title":"Neurology"},{"issue":"3","key":"9969_CR8","doi-asserted-by":"publisher","first-page":"476","DOI":"10.2967\/jnumed.113.120618","volume":"54","author":"KA Johnson","year":"2013","unstructured":"Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Carrillo MC, Hartley DM, Hedrick S, Pappas V, Thies WH (2013) Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. J Nucl Med 54(3):476\u2013490","journal-title":"J Nucl Med"},{"key":"9969_CR9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.msard.2018.10.109","volume":"27","author":"P Luczynski","year":"2019","unstructured":"Luczynski P, Laule C, Hsiung GR, Moore GRW, Tremlett H (2019) Coexistence of multiple sclerosis and Alzheimer's disease: a review. Mult Scler Relat Disord 27:232\u2013238","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"9969_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1136\/jnnp-2013-305450","volume":"85","author":"IS Mackenzie","year":"2014","unstructured":"Mackenzie IS, Morant SV, Bloomfield GA, MacDonald TM, O'Riordan J (2014) Incidence and prevalence of multiple sclerosis in the UK 1990\u20132010: a descriptive study in the General Practice Research Database. J Neurol Neurosurg Psychiatry 85(1):76\u201384","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"15 Supplement","key":"9969_CR11","doi-asserted-by":"crossref","first-page":"S49.003","DOI":"10.1212\/WNL.92.15_supplement.S49.003","volume":"92","author":"JA Matias-Guiu","year":"2019","unstructured":"Matias-Guiu JA, Pytel V, Cabrera-Mart\u00edn MN, Cort\u00e9s-Mart\u00ednez A, Moreno-Ramos T, Carreras JL, Matias-Guiu J (2019) Amyloid PET in multiple sclerosis predicts cognitive decline at 18 months (S49.003). Neurology 92(15 Supplement):S49.003","journal-title":"Neurology"},{"issue":"12","key":"9969_CR12","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1007\/s00415-015-7904-3","volume":"262","author":"RW Paterson","year":"2015","unstructured":"Paterson RW, Toombs J, Slattery CF, Nicholas JM, Andreasson U, Magdalinou NK, Blennow K, Warren JD, Mummery CJ, Rossor MN, Lunn MP, Crutch SJ, Fox NC, Zetterberg H, Schott JM (2015) Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis. J Neurol 262(12):2722\u20132730","journal-title":"J Neurol"},{"issue":"13","key":"9969_CR13","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, Hendrix J, Hillner BE, Olson C, Lesman-Segev OH, Romanoff J, Siegel BA, Whitmer RA, Carrillo MC (2019) Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA 321(13):1286\u20131294","journal-title":"JAMA"},{"issue":"3","key":"9969_CR14","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/00019052-199506000-00010","volume":"8","author":"SM Rao","year":"1995","unstructured":"Rao SM (1995) Neuropsychology of multiple sclerosis. Curr Opin Neurol 8(3):216\u2013220","journal-title":"Curr Opin Neurol"},{"issue":"17","key":"9969_CR15","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1212\/WNL.0b013e3182703f46","volume":"79","author":"MM Schoonheim","year":"2012","unstructured":"Schoonheim MM, Popescu V, Rueda Lopes FC, Wiebenga OT, Vrenken H, Douw L, Polman CH, Geurts JJ, Barkhof F (2012) Subcortical atrophy and cognition: sex effects in multiple sclerosis. Neurology 79(17):1754\u20131761","journal-title":"Neurology"},{"issue":"4","key":"9969_CR16","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/brain\/awn030","volume":"131","author":"NL Sicotte","year":"2008","unstructured":"Sicotte NL, Kern KC, Giesser BS, Arshanapalli A, Schultz A, Montag M, Wang H, Bookheimer SY (2008) Regional hippocampal atrophy in multiple sclerosis. Brain 131(4):1134\u20131141","journal-title":"Brain"},{"issue":"Pt 1","key":"9969_CR17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/brain\/awv337","volume":"139","author":"MD Steenwijk","year":"2016","unstructured":"Steenwijk MD, Geurts JJ, Daams M, Tijms BM, Wink AM, Balk LJ, Tewarie PK, Uitdehaag BM, Barkhof F, Vrenken H, Pouwels PJ (2016) Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant. Brain 139(Pt 1):115\u2013126","journal-title":"Brain"},{"issue":"5","key":"9969_CR18","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1177\/1352458515604382","volume":"22","author":"W Tobin","year":"2016","unstructured":"Tobin W, Popescu B, Lowe V, Pirko I, Parisi J, Kantarci K, Fields J, Bruns M, Boeve B, Lucchinetti C (2016) Multiple sclerosis masquerading as Alzheimer-type dementia: clinical, radiological and pathological findings. Multiple Scler J 22(5):698\u2013704","journal-title":"Multiple Scler J"},{"issue":"7","key":"9969_CR19","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1136\/jnnp.74.7.872","volume":"74","author":"M Zarei","year":"2003","unstructured":"Zarei M, Chandran S, Compston A, Hodges J (2003) Cognitive presentation of multiple sclerosis: evidence for a cortical variant. J Neurol Neurosurg Psychiatry 74(7):872\u2013877","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"9969_CR20","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/ana.25684","volume":"87","author":"B Zeydan","year":"2020","unstructured":"Zeydan B, Lowe VJ, Reichard RR, Przybelski SA, Lesnick TG, Schwarz CG, Senjem ML, Gunter JL, Parisi JE, Machulda MM, Vemuri P, Mielke MM, Knopman DS, Petersen RC, Jack CR Jr, Kantarci OH, Kantarci K (2020) Imaging biomarkers of Alzheimer disease in multiple sclerosis. Ann Neurol 87(4):556\u2013567","journal-title":"Ann Neurol"},{"issue":"6","key":"9969_CR21","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1177\/1352458517707346","volume":"24","author":"B Zeydan","year":"2018","unstructured":"Zeydan B, Lowe VJ, Schwarz CG, Przybelski SA, Tosakulwong N, Zuk SM, Senjem ML, Gunter JL, Roberts RO, Mielke MM, Benarroch EE, Rodriguez M, Machulda MM, Lesnick TG, Knopman DS, Petersen RC, Jack CR Jr, Kantarci K, Kantarci OH (2018) Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. Mult Scler 24(6):739\u2013749","journal-title":"Mult Scler"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-09969-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-020-09969-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-09969-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T22:24:55Z","timestamp":1723069495000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-020-09969-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,18]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["9969"],"URL":"https:\/\/doi.org\/10.1007\/s00415-020-09969-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,18]]},"assertion":[{"value":"22 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"RP previously sat on an advisory board for Lilly and currently has no funding or support from any organisation involved in amyloid PET imaging, and, in particular, no funding or support from the manufacturer of the only commercially available ligand. ZW was previously also participated in the Eli Lilly PET advisory board and was an amyloid PET read trainer.\u00a0CC has taken part in an advisory panel for Roche pharmaceuticals. PM has given an educational talk at a meeting organised by GE.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed were in accordance with the 1964 Helsinki declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}